Patent: 9,526,791
✉ Email this page to a colleague
Summary for Patent: 9,526,791
Title: | Weakly acidic pH-responsive peptide and liposome containing same |
Abstract: | A problem to be solved by the present invention is to provide a peptide compound for producing a drug delivery carrier capable of releasing a target substance in a weakly acidic pH environment. The present invention provides a peptide compound comprising a hydrophilic amino acid block and a hydrophobic amino acid block; [1] the peptide compound containing 24 to 36 amino acids in total; [2] the hydrophilic amino acid block containing 4 to 10 amino acids in total and having an average hydropathy index of -3.0 to -1.0; and [3] the hydrophobic amino acid block containing 20 to 32 amino acids in total, containing one or more His residues, and having an average hydropathy index of 1.0 to 2.5. |
Inventor(s): | Kogure; Kentaro (Otsu, JP), Hama; Susumu (Otsu, JP) |
Assignee: | Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) |
Application Number: | 14/430,723 |
Patent Claims: | see list of patent claims |
Details for Patent 9,526,791
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2032-10-22 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2032-10-22 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-10-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |